Max Crouse, MD
Family Medicine · Brentwood, TNNPI 1548827124
Payments from drug & device makers
Across 299 payments — averaging $19.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$726
- Pfizer$554
- GSK$500
- Lilly USA, LLC$463
- AstraZeneca$434
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,699100%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 57 | $1,110 |
| AbbVie | 39 | $726 |
| Pfizer | 29 | $554 |
| GSK | 28 | $500 |
| Lilly USA, LLC | 27 | $463 |
| AstraZeneca | 22 | $434 |
| Exact Sciences | 19 | $336 |
| Astellas Pharma US Inc | 7 | $129 |
| Bayer | 6 | $122 |
| BETA Bionics, Inc. | 2 | $114 |
| Inspire Medical Systems, Inc. | 4 | $111 |
| Abbott | 6 | $104 |
| Dynavax Technologies Corporation | 5 | $100 |
| Sanofi-aventis U.S. LLC | 6 | $85 |
| Lundbeck LLC | 4 | $81 |
| Dexcom, Inc. | 4 | $74 |
| Amgen | 4 | $59 |
| Boehringer Ingelheim | 3 | $53 |
| Johnson & Johnson | 3 | $50 |
| Xeris Pharmaceuticals, Inc. | 2 | $48 |
| Cequr Corporation | 1 | $47 |
| Abiomed | 1 | $40 |
| Idorsia Pharmaceuticals US Inc | 2 | $34 |
| Nestle Healthcare Nutrition Inc. | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Merck | 2 | $33 |
| Optinose US, Inc. | 1 | $26 |
| Si-bone, Inc. | 1 | $25 |
| Currax Pharmaceuticals LLC | 1 | $25 |
| Teleflex LLC | 1 | $23 |
| Verrica Pharmaceuticals Inc. | 1 | $23 |
| Impel Pharmaceuticals Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Seqirus USA Inc | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $16 |
How this compares
$5,724 in reported general payments places this provider in the 80th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 84 | $87,705 |
| EliquisApixaban | 46 | $59,598 |
| MounjaroTirzepatide | 26 | $40,385 |
| XareltoRivaroxaban | 30 | $32,328 |
| FarxigaDapagliflozin Propanediol | 38 | $32,034 |
| JardianceEmpagliflozin | 21 | $30,545 |
| RybelsusSemaglutide | 17 | $29,195 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $28,964 |
| JanuviaSitagliptin Phosphate | 28 | $28,253 |
| LinzessLinaclotide | 17 | $14,846 |
| MyrbetriqMirabegron | 19 | $12,021 |
| EntrestoSacubitril/Valsartan | 13 | $8,411 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 58 | $6,893 |
| Atorvastatin Calcium | 420 | $5,602 |
| Bupropion XlBupropion Hcl | 91 | $3,709 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,110 | $116,900101 claims |
| PfizerEliquis | $554 | $59,59846 claims |
| Lilly USA, LLCMounjaro | $463 | $40,38526 claims |
| Johnson & JohnsonXarelto | $50 | $32,32830 claims |
| AstraZenecaFarxiga | $434 | $32,03438 claims |
| Boehringer IngelheimJardiance | $53 | $30,54521 claims |
| GSKTrelegy Ellipta | $500 | $28,96437 claims |
| MerckJanuvia | $33 | $28,25328 claims |
| AbbVieLinzess, Synthroid | $726 | $17,74850 claims |
| Astellas Pharma US IncMyrbetriq | $129 | $12,02119 claims |
| Sanofi-aventis U.S. LLCLantus | $85 | $3,64512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Brentwood
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.